Imperial College London

DrJoanneEvans

Faculty of MedicineDepartment of Surgery & Cancer

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

joanne.evans

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Summary

Joanne is a NIHR Academic Clinical Fellow in Medical Oncology, working within the Division of Surgery and Cancer at Imperial College.  She is now in her final year of Specialist Registrar training on the prestigious Imperial Rotation.

Joanne qualified from Barts and The London School of Medicine and Dentistry (University of London) in 2009, with Distinction.  She graduated with several prizes and honours, including the Charrington prize, the Haking prize, the Enid Linder elective award, and College Merit Awards at all stages of study. She was also the recipient of multiple Richard Stapley Educational Trust awards, and the McMee Award from the Worshipful Company of Barbers. She completed Academic Foundation Training (Medical Education) and Core Medical Training in East London, where she was heavily involved in teaching. She was admitted as a member of the Royal College of Physicians (MRCP) in 2012, and completed her Specialty Certificate Examination in Medical Oncology in 2016.

Joanne came to medicine late, initially training as a basic medical scientist.  Her BSc, in Genetics at the University of Wales, Swansea, was conducted under the tutelage of Prof Jim Parry.  Here she developed an interest in genetic toxicology and mutagenesis, especially in regard to GI cancers.  While studying at Swansea, she took a year out to obtain Industrial experience, developing an extended-term human lymphocyte line that could be used in high-throughput genetic toxicology assays, helping to reduce the dependency on animal models.  This work lead to the award of a competitive bursary to aid the completion of her undergraduate studies.

Joanne undertook her D.Phil at the University of Oxford and the MRC Radiation and Genome Stability Unit, funded by the MRC and under the supervision of Prof Pete O'Neil and Drs Tim Humphrey and Steve Kearney.  Here, using the model organism Schizosaccharomyces pombe, she investigated the repair of complex DNA double strand breaks, identifying synergy between the cell cycle and Homologous Recombination repair pathways.  During this time she was awarded an 'European Commission High Scientific Impact Research' Fellowship.  She has maintained an interest in the Cell Cycle and DNA damage and repair ever since.

Her current research interests include epigenetic modification in neuroendocrine tumours (and the potential ability to transiently reverse such processes to utilize for treatment targets),  the concept of inducing site-specific synthetic lethality in tumours (sparing normal tissue), utilizing induced aberrations in multiple key DNA damage repair pathways, and the identification of treatment directing and prognostic biomarkers.  She is also interest in liver directed therapy of NET metastasis, and in early diagnostic signatures in Hepatocellular Carcinoma.

Her other interests include medical education, and she is an active contributor to undergraduate teaching and training at Imperial College, London and within Imperial College Healthcare NHS Trust, and patient engagement and partnership in research and communication.

Publications

Journals

Black J, Atkinson S, Singh A, et al., 2019, The inflammation-based index can predict response and improve patient selection in NETs treated with PRRT: a pilot study, Journal of Clinical Endocrinology and Metabolism, Vol:104, ISSN:0021-972X, Pages:285-292

Khan SA, McClements S, Reccia I, et al., 2016, The next generation of hepatocellular cancer experts: what do they think?, Hepat Oncol, Vol:3, Pages:213-215

Conference

Evans J, Kitson R, Shah R, et al., 2018, 30-day mortality following initiation of immunotherapy for advanced stage lung cancer, 16th Annual Meeting of the British Thoracic Oncology Group, Elsevier, ISSN:0169-5002

Sharma R, Wang WM, Evans J, et al., 2017, 68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs), ASCO, American Society of Clinical Oncology, ISSN:0732-183X

Yen C, Sharma R, Rimassa L, et al., 2017, Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study, International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, ELSEVIER SCIENCE BV, Pages:S223-S224, ISSN:0168-8278

More Publications